Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | FOS | P01100 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563576 | 1.00 | PIM1 (0.45) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30507875 | 0.86 | ALDH1A1 (0.60) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1052398 | 0.86 | ALDH1A1 (0.60) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29405976 | 0.86 | ALDH1A1 (0.60) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1052400 | 0.86 | ALDH1A1 (0.60) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5640399 | 0.86 | PIM1 (0.48) | PIM1PIM2ALDH1A1 | |
| SCHEMBL2660249 | 0.85 | PIM1 (0.45) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5181108 | 0.85 | GLA (0.50) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2660253 | 0.85 | PIM1 (0.45) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5181111 | 0.85 | GLA (0.50) | PIM1PIM2KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100345845-C | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | CN | disclosed |
| EP-1622896-B1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-7205326-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| CN-1780830-A | Aniline derivatives, process for their preparation and their use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | disclosed |
| EP-1622896-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004096796-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | ERBB2, EGFR, ERBB3 | PIM1 1276/4885PIM2 843/4885KDM4E 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.